Meet the Team

OHE's exceptional team has strong expertise in the economics and statistics of health care provision and financing, the pricing and regulation of pharmaceuticals, and health technology assessment (HTA). Our experts have joined us from government, the life sciences industries, consultancies and academia. Supplementing our in-house expertise is an extensive network of health policy, economics and statistical experts based in the UK, Europe and around the world.

We emphasise activities that maintain the strength of our expertise, ensuring that both our research and consulting activities provide the best value possible. Each of our senior staff holds an academic appointment and we actively encourage our research and consultancy staff to publish and participate in conferences and seminars.

The OHE team are listed below:


Adrian’s current research includes the use of 'risk-sharing' arrangements between health care payers and pharmaceutical companies, including value-based pricing approaches; the economics of pharmacogenetics for health care payers and the pharmaceutical industry; economic issues that affect both R&D for and access to treatments for diseases prevalent in the developing world;

Director Designate

Professor Graham Cookson is Director Designate at the Office of Health Economics, and will take over the role of Director from Professor Adrian Towse on 1st January 2019.

Graham is an econometrician by training and is interested in the use of big data in health and life sciences research. His current research interests include the measurement and determinants of productivity in healthcare especially labour productivity; the industrial organisation of healthcare especially tariffs and competition; real-world evidence in health economic evaluation; and big data in the health and life sciences. He is best known for this work on the economics of staffing and skill mix in the English NHS, and this research was critical to the development of the NICE Guidelines on Safe Staffing.

Deputy Director & Director of Consulting

Paula has over 15 years’ experience working in academia in Australia and the United Kingdom. Her research spans three key areas of health economics: the determinants of health, economic evaluation and outcome measurement. She is currently working in the clinical areas of oncology, including genomic testing; maternal mental health; HIV; and workplace health promotion.

Director of Research

Nancy's principal areas of research expertise are the measurement and valuation of patient reported health outcomes; the cost effectiveness thresholds used in making judgments about value for money in health care; use of MCDA in health care decision making; priority setting in health care; and measuring the production, performance and efficiency of hospitals.


Mikel’s current research interests are the economics of the pharmaceutical industry; including innovation and incentives for encouraging medical R&D, regulation of pharmaceutical markets and social welfare analysis, and competition and incentives for health care providers.


Amanda’s current research interests include the use of real world evidence to support HTA and product development; novel pricing and reimbursement mechanisms for pharmaceuticals (e.g. managed entry agreements and the economics of indication-based pricing); health state valuation methodology; criteria for the economic evaluation of health interventions; and the interaction between HTA policy and optimal R&D decisions by industry


Patricia’s main areas of research are: health-related quality of life measures, subjective well-being, cost-effectiveness thresholds, estimation of health-related outcomes, health policy evaluation, adaptation to health states, ordered choice models and theory of preferences.

Principal Economist

Martina’s current research includes economic issues posed by the development and provision of treatments for rare diseases; the economics of personalised medicine for health care payers and the pharmaceutical industry; and approaches to value based assessments.

Personal Assistant to the Directors

Claire's key responsibility is time management and administrative support for the Directors. Prior to joining the OHE in 2008, Claire worked as a PA for Halcrow Group Limited for three years where her responsibilities included providing PA support to the regional managing director. Claire has a degree in psychology.

Senior Economist

Grace’s areas of expertise include health technology appraisal, economic modelling and clinical guidelines. Grace is also interested in the economic evaluation of diagnostics and patient stratification, early stage modelling, and the economic evaluation of regenerative medicines and other high cost therapies. Grace has recently been appointed to NICE’s Clinical Guidelines Update Standing Committee, where she provides expert advice on the economic implications of NICE’s clinical guideline recommendations.

Team Assistant

Amy joined OHE at the start of June 2017. Her role involves providing general office support to the team, data collection and reporting at the organisational level, assisting with the production of publications, maintaining the organisations’ website, posting regular updates on social media, and helping co-ordinate promotional activities.



Margherita joined the OHE in December 2016 as Economist. Her work at the OHE has involved a number consulting projects, relating to different aspects of pharmaceutical R&D and HTA activities. She has experience in supporting the development of internal strategies for pharmaceutical companies in defining the value proposition of their pipeline (e.g. value frameworks) and the evidence generation processes during the product lifecycle.

Head of Information and Analysis

Phill's research interests include the economics of the pharmaceutical market, the productivity and outputs of NICE, and benchmarking industry performance. He has extensive knowledge of, and experience with, data and other information used to understand the medicines market and performance of the pharmaceutical industry.


Marina’s research interests focus on the evaluation of healthcare programmes’ effectiveness, focusing on quality of life factors that impact budgets and decision making. She is also interested in the economics of health care systems in emerging markets.


Olga’s research interests are in the field of industrial organisation, including questions relating to competition, regulation and R&D incentives. 
She holds a PhD from the Toulouse School of Economics. In her dissertation she analysed the effects of market structure and various regulatory schemes on producers’ incentives to invest in quality improvement.  


Chris’s primary research interest is economic evaluation in health care, including the development of new methods for cost-effectiveness analysis and the valuation of health. He has worked on trial- and model-based economic evaluations in a variety of clinical fields. Chris is also dedicated to building new platforms for collaboration in the discipline of health economics.

Principal Economist

Koonal's research interests include health state valuation methodology and the use of social value judgements in health care decision making. He has published over 30 journal articles and book chapters on these topics, and has led research and consulting projects for health care providers, research foundations, policy makers and global pharmaceutical companies.

Business Executive

Kerry's responsibilities include maintaining the website, overseeing the production and publishing of in-house publications, organising events and serving as the contact point for accounts. Before joining the OHE in 2000, she was with the ABPI.


Bernarda’s areas of expertise include econometric modelling of health statistics at patient level and also international health statistics at country level. Prior to joining OHE in 2015, Bernarda has worked in Spanish and British academia and international organisations. She holds a PhD in Economics from the University Carlos III of Madrid and a Certificate in Quantitative Finance from Fitch Learning.